Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17392565 | 1.00 | HPGD (0.51) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL13219346 | 1.00 | HPGD (0.51) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL1024755 | 0.93 | HPGD (0.54) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL4334069 | 0.91 | HPGD (0.52) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL29244745 | 0.91 | HPGD (0.52) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL7299784 | 0.87 | HPGD (0.51) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL6988508 | 0.87 | HPGD (0.51) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL435844 | 0.86 | NR1H2 (0.50) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL9836659 | 0.86 | HPGD (0.50) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL21938019 | 0.86 | HPGD (0.50) | HPGDRECQLEPHX1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116745280-A | Bifunctional compounds for degrading EGFR and related methods of use | 百济神州有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-3882239-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2021-09-22 | — | — | EP | disclosed |
| CN-113302184-A | 1,3, 4-oxadiazolinone compounds and drugs | 日本新药株式会社 | 2021-08-24 | — | — | CN | disclosed |
| WO-2017120164-A1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Tabomedex Biosciences, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| US-9580416-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580416-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580416-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160002225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | SCHRODINGER, LLC | 2016-01-07 | — | — | US | disclosed |
| US-20160002225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | SCHRODINGER, LLC | 2016-01-07 | — | — | US | disclosed |
| WO-2016004272-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2016-01-07 | — | — | WO | disclosed |
| US-20160002225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | SCHRODINGER, LLC | 2016-01-07 | — | — | US | disclosed |
| US-8129546-B2 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129546-B2 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110077269-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077269-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| US-7842819-B2 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842819-B2 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-20070203122-A1 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| US-20070203122-A1 | Derivatives for modulation of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-30 | — | — | US | disclosed |
| WO-2007050522-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203122-A1 | Derivatives for modulation of ion channels | TRPV1, TRPA1, TRPV2 | HPGD 1667/4885RECQL 4079/4885EPHX1 2702/4885 |
| US-20160002225-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | HPGD 3678/4885RECQL 972/4885EPHX1 2435/4885 |
| US-20110077269-A1 | DERIVATIVES FOR MODULATION OF ION CHANNELS | TRPV1, TRPA1, TRPV2 | HPGD 1667/4885RECQL 4079/4885EPHX1 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.